ADMA Biologics, Inc. (ADMA)
9.23
-0.16
(-1.70%)
USD |
NASDAQ |
Sep 11, 16:00
9.235
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Enterprise Value : 2.148B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 2.148B |
| September 10, 2026 | 2.184B |
| September 09, 2026 | 2.197B |
| September 08, 2026 | 2.218B |
| September 04, 2026 | 2.236B |
| September 03, 2026 | 2.227B |
| September 02, 2026 | 2.211B |
| September 01, 2026 | 2.170B |
| August 31, 2026 | 2.184B |
| August 28, 2026 | 2.173B |
| August 27, 2026 | 2.204B |
| August 26, 2026 | 2.238B |
| August 25, 2026 | 2.258B |
| August 24, 2026 | 2.220B |
| August 21, 2026 | 2.285B |
| August 20, 2026 | 2.267B |
| August 19, 2026 | 2.333B |
| August 18, 2026 | 2.218B |
| August 17, 2026 | 2.173B |
| August 14, 2026 | 2.202B |
| August 13, 2026 | 2.188B |
| August 12, 2026 | 2.272B |
| August 11, 2026 | 2.300B |
| August 10, 2026 | 2.265B |
| August 07, 2026 | 2.299B |
| Date | Value |
|---|---|
| August 06, 2026 | 2.335B |
| August 05, 2026 | 2.155B |
| August 04, 2026 | 2.076B |
| August 03, 2026 | 2.037B |
| July 31, 2026 | 1.974B |
| July 30, 2026 | 2.022B |
| July 29, 2026 | 2.031B |
| July 28, 2026 | 2.049B |
| July 27, 2026 | 1.979B |
| July 24, 2026 | 1.932B |
| July 23, 2026 | 1.954B |
| July 22, 2026 | 1.956B |
| July 21, 2026 | 2.004B |
| July 20, 2026 | 2.040B |
| July 17, 2026 | 2.031B |
| July 16, 2026 | 2.053B |
| July 15, 2026 | 2.024B |
| July 14, 2026 | 2.067B |
| July 13, 2026 | 2.089B |
| July 10, 2026 | 2.114B |
| July 09, 2026 | 2.157B |
| July 08, 2026 | 2.132B |
| July 07, 2026 | 2.143B |
| July 06, 2026 | 2.132B |
| July 02, 2026 | 2.085B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Erasca, Inc. | 4.739B |
| Vericel Corp. | 1.894B |
| BioMarin Pharmaceutical, Inc. | 16.06B |
| Emergent BioSolutions, Inc. | 766.90M |
| Exelixis, Inc. | 13.29B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.82M |
| Revenue (Quarterly) | 124.40M |
| Total Expenses (Quarterly) | 86.57M |
| EPS Diluted (Quarterly) | 0.1642 |
| Gross Profit Margin (Quarterly) | 69.31% |
| Profit Margin (Quarterly) | 30.40% |
| Earnings Yield | 7.63% |
| Operating Earnings Yield | 9.79% |
| Normalized Earnings Yield | 7.700 |